Zacks Investment Research Lowers Seres Therapeutics, Inc. (MCRB) to Sell

Seres Therapeutics, Inc. (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other equities research analysts also recently issued reports on MCRB. BidaskClub raised Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target (up from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $17.50.

Seres Therapeutics (NASDAQ:MCRB) opened at 11.50 on Wednesday. Seres Therapeutics has a one year low of $8.86 and a one year high of $17.42. The company has a 50-day moving average price of $14.50 and a 200-day moving average price of $14.50. The stock’s market cap is $465.89 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.70) earnings per share. On average, analysts anticipate that Seres Therapeutics will post ($2.55) earnings per share for the current year.

WARNING: This news story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/11/zacks-investment-research-lowers-seres-therapeutics-inc-mcrb-to-sell.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its position in Seres Therapeutics by 1.1% during the second quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock worth $410,000 after buying an additional 400 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Seres Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock worth $206,000 after buying an additional 2,410 shares in the last quarter. State Street Corp grew its position in Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock worth $3,637,000 after buying an additional 34,393 shares in the last quarter. Voya Investment Management LLC acquired a new stake in Seres Therapeutics during the second quarter worth about $114,000. Finally, Dimensional Fund Advisors LP grew its position in Seres Therapeutics by 45.7% during the second quarter. Dimensional Fund Advisors LP now owns 36,600 shares of the biotechnology company’s stock worth $414,000 after buying an additional 11,488 shares in the last quarter. 74.76% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target (up from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $17.50.

Seres Therapeutics (NASDAQ:MCRB) opened at 11.50 on Wednesday. Seres Therapeutics has a one year low of $8.86 and a one year high of $17.42. The company has a 50-day moving average price of $14.50 and a 200-day moving average price of $14.50. The stock’s market cap is $465.89 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.70) earnings per share. On average, analysts anticipate that Seres Therapeutics will post ($2.55) earnings per share for the current year.

WARNING: This news story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/11/zacks-investment-research-lowers-seres-therapeutics-inc-mcrb-to-sell.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its position in Seres Therapeutics by 1.1% during the second quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock worth $410,000 after buying an additional 400 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Seres Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock worth $206,000 after buying an additional 2,410 shares in the last quarter. State Street Corp grew its position in Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock worth $3,637,000 after buying an additional 34,393 shares in the last quarter. Voya Investment Management LLC acquired a new stake in Seres Therapeutics during the second quarter worth about $114,000. Finally, Dimensional Fund Advisors LP grew its position in Seres Therapeutics by 45.7% during the second quarter. Dimensional Fund Advisors LP now owns 36,600 shares of the biotechnology company’s stock worth $414,000 after buying an additional 11,488 shares in the last quarter. 74.76% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply